抗凝治療在肺心病治療中的臨床應(yīng)用價(jià)值

劉鎮(zhèn)林

【摘要】目的 探究肺心病患者采用抗凝治療的臨床效果。方法 選取本院2015年7月～2017年5月收治的肺心病患者96例，并根據(jù)雙盲法分為2組，對(duì)照組與觀察組分別予以常規(guī)治療與抗凝治療，并對(duì)比2組患者臨床效果、癥狀消失時(shí)間、治療時(shí)間、全血低切粘度、血漿粘度、紅細(xì)胞比容、全血高切粘度、紅細(xì)胞聚集指數(shù)、凝血酶原片段、纖維蛋白原、血小板膜蛋白-140、二氧化碳分壓、氧分壓水平以及不良反應(yīng)。

結(jié)果 觀察組患者總有效率91.67%，高于對(duì)照組的72.92%，（P<0.05）；觀察組患者癥狀消失時(shí)間與治療時(shí)間都少于對(duì)照組（P<0.05）；觀察組患者全血低切粘度、血漿粘度、紅細(xì)胞比容、全血高切粘度、紅細(xì)胞聚集指數(shù)均低于對(duì)照組（P<0.05）；觀察組患者凝血酶原片段、纖維蛋白原、血小板膜蛋白-140、二氧化碳分壓都低于對(duì)照組（P<0.05）；觀察組患者的氧分壓水平高于對(duì)照組（P<0.05）；2組患者治療期間都沒(méi)有產(chǎn)生藥物不良反應(yīng)。結(jié)論 抗凝治療在對(duì)肺心病的治療過(guò)程中，縮短癥狀消失時(shí)間與治療時(shí)間可使患者的血液流變學(xué)指標(biāo)、血?dú)庵笜?biāo)以及凝血參數(shù)明顯改善，不良反應(yīng)較少，使患者的治療效果進(jìn)一步提高。

【關(guān)鍵詞】抗凝治療；肺心病；應(yīng)用價(jià)值

【中圖分類號(hào)】R541.5 【文獻(xiàn)標(biāo)識(shí)碼】A 【文章編號(hào)】ISSN.2095-6681.2018.02..03

【Abstract】Objective To explore the clinical effect of anticoagulant therapy in patients with pulmonary heart disease.Methods 96 patients with pulmonary heart disease in our hospital from July 2015～2017 year in May according to the double blind method divided into 2 groups.Results in the observation group，the total efficiency of 91.67%， higher than 72.92% of the control group（P<0.05）；patients in the observation group symptoms disappeared time and treatment time were less than the control group （P<0.05）； patients in the observation group the whole blood viscosity， plasma viscosity， hematocrit，whole blood viscosity， erythrocyte aggregation index were lower than the control group （P<0.05）； patients in the observation group， prothrombin fragment fibrinogen， platelet membrane protein -140， partial pressure of carbon dioxide is lower than that of the control group （P<0.05）；the observation group of patients with oxygen levels higher than the control group （P<0.05）； the 2 groups of patients during treatment were no adverse drug reactions.Conclusion anticoagulant therapy in the treatment of pulmonary heart disease， shorten the treatment time and the symptoms disappear time can make the patient's blood rheology， blood gas index and

coagulation parameters improved significantly，less adverse reaction， so that the treatment effect of the patients further.

【Key words】Anticoagulant therapy；Pulmonary heart disease；Application value

慢性肺源性心臟病（chronic cor pulmonale）是由肺組織、肺動(dòng)脈血管或胸廓的慢性病變引起肺組織結(jié)構(gòu)和功能異常，產(chǎn)生肺血管阻力增加，肺動(dòng)脈壓力增高，使右心擴(kuò)張、肥大，伴或不伴右心衰竭的心臟病。它可以發(fā)生于老年人，但多數(shù)是從中年遷延發(fā)展而來(lái)。老年肺心病大多是從慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）發(fā)展而來(lái)。……